Contineum Therapeutics, Inc.
Contineum Therapeutics, Inc. (CTNM): 4 pipeline candidates · ~44 mo cash runway · 2 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
43.7 months
D/E 0.05
Lead: Phase 2
4 candidates
N/A
0 buys · 21 sells (180d)
A transparent, data-derived signal for Contineum Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$475.6M
Cash
$20.2M
Quarterly Burn
$16.3M
Runway
43.7 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (4 candidates)
| Drug | Phase |
|---|---|
| PIPE-307 | Phase 2 |
| PIPE-791 | Phase 2 |
| pipe-791 dose a | Phase 2 |
| pipe-791 dose b | Phase 2 |
Frequently asked questions
How many drug candidates are in Contineum Therapeutics, Inc.'s pipeline?
Contineum Therapeutics, Inc. (CTNM) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Contineum Therapeutics, Inc.'s lead drug candidate?
Contineum Therapeutics, Inc.'s most advanced tracked candidate is PIPE-307 (Phase 2) for Chronic Osteoarthritis Pain.
What is Contineum Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Contineum Therapeutics, Inc. has approximately 43.7 months of cash runway.
What is Contineum Therapeutics, Inc.'s market capitalization?
Contineum Therapeutics, Inc.'s market capitalization is approximately $475.6M.
Who is the CEO of Contineum Therapeutics, Inc.?
Mr. Carmine N. Stengone MBA, MS is the chief executive officer of Contineum Therapeutics, Inc. (CTNM).
Get the full picture on Contineum Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.